Dipyridyl

Dipyridyl

SCHEMBL497901

[Cu].c1ccc(-c2ccccn2)nc1

nearest known ligand 0.93

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.93
LMNA P02545 3/20 0.93
CCR1 P32246 3/20 0.93
CCR5 P51681 3/20 0.93
CCR8 P51685 3/20 0.93
CYP1A2 P05177 1/20 0.93
POLB P06746 1/20 0.93
METAP1 P53582 1/20 0.93
BLM P54132 1/20 0.93
HIF1A Q16665 1/20 0.93
DOHH Q9BU89 1/20 0.93
P4HTM Q9NXG6 1/20 0.93
NPC1 O15118 6/20 0.74
TP53 P04637 4/20 0.74
RAB9A P51151 4/20 0.74
ALOX15 P16050 3/20 0.74
SMN1; SMN2 Q16637 3/20 0.74
L3MBTL1 Q9Y468 3/20 0.74
HTT P42858 2/20 0.74
TDP1 Q9NUW8 2/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dipyridyl SCHEMBL15136892 1.00 KDM4E (0.93) KDM4ELMNACCR1CCR5CCR8
Dipyridyl SCHEMBL3799914 1.00 KDM4E (0.93) KDM4ELMNACCR1CCR5CCR8
Dipyridyl SCHEMBL2371023 1.00 KDM4E (0.93) KDM4ELMNACCR1CCR5CCR8
Dipyridyl SCHEMBL18065641 1.00 KDM4E (0.93) KDM4ELMNACCR1CCR5CCR8
Dipyridyl SCHEMBL1237608 1.00 KDM4E (0.93) KDM4ELMNACCR1CCR5CCR8
Dipyridyl SCHEMBL8716183 1.00 KDM4E (0.93) KDM4ELMNACCR1CCR5CCR8
Dipyridyl SCHEMBL7909040 1.00 KDM4E (0.93) KDM4ELMNACCR1CCR5CCR8
Dipyridyl SCHEMBL6749371 0.97 KDM4E (0.88) KDM4ELMNACCR1CCR5CCR8
Dipyridyl SCHEMBL28482248 0.97 KDM4E (0.88) KDM4ELMNACCR1CCR5CCR8
Dipyridyl SCHEMBL29115681 0.97 KDM4E (0.88) KDM4ELMNACCR1CCR5CCR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118304940-B Copper-doped bipyridine Zr-MOF catalyst and preparation method and application thereof 广东工业大学 2024-09-03 CN claimed
CN-118345385-A Preparation method of catalytic material containing organic compound and used for preparing ethanol 北方工业大学 2024-07-16 CN claimed
CN-118304940-A Copper-doped bipyridine Zr-MOF catalyst and preparation method and application thereof 广东工业大学 2024-07-09 CN claimed
US-11872547-B2 Process for the photocatalytic allylic oxidation of olefins using carbon dioxide COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2024-01-16 US claimed
CN-117334850-A Modification method of lithium metal and application thereof 电子科技大学 2024-01-02 CN claimed
US-11530458-B2 Methods of using multi-ligand metal complexes to perform oxidative catalytic pretreatment of lignocellulosic biomass BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) 2022-12-20 US claimed
US-20220314208-A1 PROCESS FOR THE PHOTOCATALYTIC ALLYLIC OXIDATION OF OLEFINS USING CARBON DIOXIDE COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2022-10-06 US claimed
CN-114702514-A 2,2' -bipyridine and uracil-1-base acetic acid copper tetrafluoroborate complex and preparation method and application thereof 温州大学新材料与产业技术研究院 2022-07-05 CN claimed
CN-113171631-B Preparation method of modified-methyl tributyroximo silane extraction separation auxiliary agent 浙江锦华新材料股份有限公司 2022-05-17 CN claimed
CN-113171631-A Preparation method of modified-methyl tributyroximo silane extraction separation auxiliary agent 浙江锦华新材料股份有限公司 2021-07-27 CN claimed
US-20200332376-A1 ECONOMICAL METHODS FOR PERFORMING OXIDATIVE CATALYTIC PRETREATMENT OF PLANT BIOMASS USING A HOMOGENEOUS CATALYST SYSTEM UNITED STATES DEPARTMENT OF ENERGY 2020-10-22 US claimed
US-20190091674-A1 METHODS OF USING MULTI-LIGAND METAL COMPLEXES TO PERFORM OXIDATIVE CATALYTIC PRETREATMENT OF LIGNOCELLULOSIC BIOMASS UNITED STATES DEPARTMENT OF ENERGY 2019-03-28 US claimed
EP-3056491-B1 SYNTHETIC INTERMEDIATE OF MAXACALCITOL, PREPARATION METHOD THEREFOR AND USE THEREOF ZHEJIANG HISUN PHARM CO LTD (CN) 2018-08-08 EP claimed
US-20160237030-A1 SYNTHETIC INTERMEDIATE OF MAXACALCITOL, PREPARATION METHOD THEREFOR AND USE THEREOF ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) 2016-08-18 US claimed
EP-3056491-A1 SYNTHETIC INTERMEDIATE OF MAXACALCITOL, PREPARATION METHOD THEREFOR AND USE THEREOF Zhejiang Hisun Pharmaceutical Co. Ltd. (CN) 2016-08-17 EP claimed
US-20150352540-A1 MULTI-LIGAND METAL COMPLEXES AND METHODS OF USING SAME TO PERFORM OXIDATIVE CATALYTIC PRETREATMENT OF LIGNOCELLULOSIC BIOMASS ENERGY, UNITED STATES DEPARTMENT OF 2015-12-10 US claimed
EP-1512006-B1 ELECTROSPRAY TANDEM MASS SPECTROMETRY FOR NEWBORN SCREENING IZAAK WALTON KILLAM HEALTH CT (CA) 2006-08-09 EP claimed
US-6800489-B2 Electrospray tandem mass spectrometry of transition metal diimine complexes of amino acids, α-hydroxyketones and hexose phosphates for newborn screening IZAAK WALTON KILLAM HEALTH CENTER (CA) 2004-10-05 US claimed
US-6043370-A REACTING AROMATIC AMINE WITH AN AROMATIC HALIDE IN PRESENCE OF COPPER CONTAINING CATALYST IN A REACTION SOLVENT HAVING IONIZATION POTENTIAL OF FROM 8.0 TO 9.0 EV. SANKIO CHEMICAL CO., LTD. (JP) 2000-03-28 US claimed
EP-0411935-A2 Copper radio sensitizers JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 1991-02-06 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160237030-A1 SYNTHETIC INTERMEDIATE OF MAXACALCITOL, PREPARATION METHOD THEREFOR AND USE THEREOF CYP24A1, CYP2R1, CYP27B1 KDM4E 4172/4885LMNA 2231/4885CCR1 349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.